Asset
Resmetirom
Madrigal Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04197479 | phase3 | completed | 2019-12-16 | 2023-01-06 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients |
| NCT04951219 | phase3 | active_not_recruiting | 2021-07-09 | 2027-03-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) |
| NCT05500222 | phase3 | active_not_recruiting | 2022-08-26 | 2026-12-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) |
| NCT03900429 | phase3 | active_not_recruiting | 2019-03-28 | 2028-01-01 | Madrigal Pharmaceuticals, Inc. | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis |
| NCT01519531 | phase1 | completed | 2012-01-01 | 2012-11-01 | Madrigal Pharmaceuticals, Inc. | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 217785 | NDA | MADRIGAL PHARMACEUTICALS INC |
Marketed products (3)
- REZDIFFRA
- REZDIFFRA
- REZDIFFRA